Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets.
Acute myeloid leukemia
CD33
CD47
LILRB4
antibody
antibody-drug conjugate
bispecific antibody
fusion protein
immunotherapy
targeted therapy
Journal
Expert opinion on investigational drugs
ISSN: 1744-7658
Titre abrégé: Expert Opin Investig Drugs
Pays: England
ID NLM: 9434197
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
pmc-release:
26
02
2024
pubmed:
11
2
2023
medline:
9
3
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is the most common and deadly type of leukemia affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed by hematopoietic stem cell transplants, but this is only possible in patients who can tolerate these harsh treatments and many are elderly and frail. With the identification of novel tumor-specific cell surface receptors, there is great conviction that targeted antibody therapies will soon become available for these patients. In this review, we describe the current landscape of known target receptors for monospecific and bispecific antibody-based therapeutics for AML. Here, we characterize each of the receptors and targeted antibody-based therapeutics in development, illustrating the rational design behind each therapeutic compound. We then discuss the bispecific antibodies in development and how they improve immune surveillance of AML. For each therapeutic, we also summarize the available pre-clinical and clinical data, including data from discontinued trials. One antibody-based therapeutic has already been approved for AML treatment, the CD33-targeting antibody-drug conjugate, gemtuzumab ozogamicin. Many more are currently in pre-clinical and clinical studies. These antibody-based therapeutics can perform tumor-specific, elaborate cytotoxic functions and there is growing confidence they will soon lead to personalized, safe AML treatment options that induce durable remissions.
Identifiants
pubmed: 36762937
doi: 10.1080/13543784.2023.2179482
pmc: PMC10031751
mid: NIHMS1874046
doi:
Substances chimiques
Sialic Acid Binding Ig-like Lectin 3
0
Gemtuzumab
93NS566KF7
Antineoplastic Agents
0
Immunoconjugates
0
Antibodies, Bispecific
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-125Subventions
Organisme : NCI NIH HHS
ID : R01 CA248736
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA263079
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121458
Pays : United States
Références
Front Immunol. 2018 Mar 02;9:398
pubmed: 29552012
Leukemia. 2014 Nov;28(11):2213-21
pubmed: 24705479
Leukemia. 2019 Feb;33(2):299-312
pubmed: 30651634
Expert Opin Biol Ther. 2019 Jul;19(7):721-733
pubmed: 31286786
Curr Opin Pharmacol. 2012 Oct;12(5):615-22
pubmed: 22920732
Am J Transl Res. 2020 Jul 15;12(7):3149-3166
pubmed: 32774691
J Exp Clin Cancer Res. 2022 Mar 14;41(1):97
pubmed: 35287686
J Clin Oncol. 2014 Sep 20;32(27):3021-32
pubmed: 25092781
Prog Tumor Res. 2016;43:87-100
pubmed: 27595359
Curr Hematol Malig Rep. 2018 Dec;13(6):417-425
pubmed: 30280288
MAbs. 2009 Sep-Oct;1(5):481-90
pubmed: 20065652
Blood Adv. 2020 Mar 10;4(5):906-919
pubmed: 32150609
Clin Cancer Res. 2017 Feb 15;23(4):1068-1079
pubmed: 27856600
EMBO Mol Med. 2012 Oct;4(10):1015-28
pubmed: 22837174
Nat Immunol. 2003 Nov;4(11):1102-10
pubmed: 14556006
Leukemia. 2019 Jan;33(1):64-74
pubmed: 29946192
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Biol Blood Marrow Transplant. 2010 May;16(5):612-21
pubmed: 20139023
Asia Pac J Clin Oncol. 2020 Jun;16(3):137-141
pubmed: 32030888
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Expert Opin Ther Targets. 2016 Aug;20(8):959-73
pubmed: 26914723
J Immunol. 2009 May 1;182(9):5208-16
pubmed: 19380766
Am J Transplant. 2006 Jan;6(1):76-82
pubmed: 16433759
J Immunol. 2008 Oct 1;181(7):4742-51
pubmed: 18802077
Am J Hematol. 2016 Mar;91(3):302-7
pubmed: 26663096
Mol Immunol. 2015 Oct;67(2 Pt A):28-45
pubmed: 25911943
Leukemia. 2013 Apr;27(5):1107-15
pubmed: 23178753
Blood. 2013 Jun 13;121(24):4854-60
pubmed: 23591789
Nature. 1958 Sep 6;182(4636):670-1
pubmed: 13590068
Leukemia. 2021 Jan;35(1):62-74
pubmed: 32203138
Nat Immunol. 2018 Jan;19(1):76-84
pubmed: 29180808
J Adv Pract Oncol. 2019 Jan-Feb;10(1):68-82
pubmed: 31308990
J Immunol. 2008 Jan 15;180(2):699-705
pubmed: 18178807
Mol Ther. 2018 Oct 3;26(10):2487-2495
pubmed: 30131301
J Clin Invest. 2015 Sep;125(9):3413-21
pubmed: 26258412
Blood. 2018 Jan 25;131(4):387-396
pubmed: 29196412
Front Oncol. 2021 May 10;11:656218
pubmed: 34041025
Front Oncol. 2022 Jan 13;11:806243
pubmed: 35096610
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Br J Clin Pharmacol. 2008 Jul;66(1):6-19
pubmed: 18503606
J Leukoc Biol. 1997 Jan;61(1):6-16
pubmed: 9000531
Expert Opin Biol Ther. 2021 Jul;21(7):795-799
pubmed: 32857943
Clin Cancer Res. 2016 Jul 15;22(14):3440-50
pubmed: 26847056
J Biol Chem. 2009 Dec 11;284(50):34839-48
pubmed: 19833736
Blood. 2017 Feb 2;129(5):609-618
pubmed: 27908880
J Biol Chem. 2011 May 20;286(20):18013-25
pubmed: 21454581
Life Sci. 2015 Feb 1;122:59-64
pubmed: 25445480
Curr Opin Immunol. 2012 Apr;24(2):225-32
pubmed: 22310103
Cancer Immunol Res. 2020 Feb;8(2):230-245
pubmed: 31852716
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
J Biol Chem. 2004 Apr 9;279(15):14792-802
pubmed: 14739280
Blood. 1997 Feb 1;89(3):842-52
pubmed: 9028315
Int Immunol. 2021 Jul 23;33(8):447-458
pubmed: 34089617
J Exp Med. 1997 Dec 1;186(11):1809-18
pubmed: 9382880
Nat Med. 2009 Sep;15(9):1010-2
pubmed: 19734877
Adv Immunol. 2006;91:251-72
pubmed: 16938543
Blood. 2014 Jan 23;123(4):554-61
pubmed: 24311721
Nat Cancer. 2021 Nov;2(11):1170-1184
pubmed: 35122056
Leukemia. 1996 Feb;10(2):238-48
pubmed: 8637232
Haematologica. 2022 Mar 01;107(3):770-773
pubmed: 34854276
Blood. 2021 Feb 11;137(6):751-762
pubmed: 32929488
Antib Ther. 2021 Feb 09;4(1):16-33
pubmed: 33928233
J Immunol. 1997 Dec 1;159(11):5192-6
pubmed: 9548455
N Engl J Med. 2019 Oct 31;381(18):1728-1740
pubmed: 31665578
Blood. 2007 Feb 1;109(3):1061-8
pubmed: 17008544
Blood. 2006 Feb 15;107(4):1459-67
pubmed: 16239426
Front Immunol. 2020 Aug 14;11:1771
pubmed: 32922390
Semin Oncol. 2020 Apr - Jun;47(2-3):117-124
pubmed: 32517874
Front Oncol. 2020 Jan 22;9:1380
pubmed: 32038992
Cells. 2019 Dec 05;8(12):
pubmed: 31817547
J Cell Mol Med. 2018 Apr;22(4):2311-2318
pubmed: 29411522
Clin Cancer Res. 2001 Jun;7(6):1490-6
pubmed: 11410481
Sci Rep. 2021 Nov 11;11(1):22062
pubmed: 34764342
J Hematother. 1995 Oct;4(5):433-7
pubmed: 8581381
Oncotarget. 2017 May 30;8(22):35707-35717
pubmed: 28415689
PLoS One. 2015 Sep 21;10(9):e0137345
pubmed: 26390038
Leukemia. 2021 Jul;35(7):1843-1863
pubmed: 33953290
Nature. 2018 Oct;562(7728):605-609
pubmed: 30333625
Int Immunol. 2015 Jul;27(7):345-55
pubmed: 25744616
Leukemia. 2012 Jun;26(6):1228-37
pubmed: 22289926
Oncoimmunology. 2016 Jun 29;5(7):e1195535
pubmed: 27622049
J Immunother Cancer. 2021 Jul;9(7):
pubmed: 34326171
J Immunol. 1994 Feb 15;152(4):1762-73
pubmed: 8120385
Cell Cycle. 2006 Feb;5(3):271-3
pubmed: 16397415
J Clin Oncol. 2012 Nov 10;30(32):3924-31
pubmed: 22851554
Immunother Adv. 2022 Aug 10;2(1):ltac019
pubmed: 36196369
J Exp Med. 2017 Feb;214(2):359-380
pubmed: 28031480
Eur J Immunol. 1999 Nov;29(11):3440-9
pubmed: 10556798
Pharmacol Ther. 2018 May;185:122-134
pubmed: 29269044
Best Pract Res Clin Haematol. 2020 Dec;33(4):101224
pubmed: 33279180
Int J Hematol. 2018 May;107(5):513-518
pubmed: 29374826
ILAR J. 2005;46(3):258-68
pubmed: 15953833
Semin Hematol. 2015 Jul;52(3):207-14
pubmed: 26111468
Cancer Immunol Res. 2019 Aug;7(8):1244-1257
pubmed: 31213474
Cell Cycle. 2016;15(1):25-40
pubmed: 26636629
Oncotarget. 2016 Sep 6;7(36):57811-57820
pubmed: 27506934
Clin Cancer Res. 2019 Jan 15;25(2):473-477
pubmed: 30254079
Adv Exp Med Biol. 2019;1143:1-39
pubmed: 31338813
Blood. 1999 Aug 15;94(4):1237-47
pubmed: 10438711
Blood. 2000 Jul 15;96(2):483-90
pubmed: 10887109
Nat Med. 2020 Sep;26(9):1459-1467
pubmed: 32601337
J Clin Invest. 2019 Nov 1;129(11):5005-5019
pubmed: 31437130
Drug Des Devel Ther. 2017 Aug 02;11:2265-2276
pubmed: 28814834
Biomedicines. 2021 Aug 06;9(8):
pubmed: 34440176
Cancer Immunol Immunother. 2013 Feb;62(2):217-23
pubmed: 23223907
Blood Adv. 2020 Nov 10;4(21):5402-5413
pubmed: 33147339
J Leukoc Biol. 2008 Feb;83(2):334-43
pubmed: 17998301
Cell Stem Cell. 2015 Sep 3;17(3):341-52
pubmed: 26279267
Expert Rev Clin Pharmacol. 2018 Jun;11(6):549-559
pubmed: 29787320
Cancer Immunol Res. 2021 Nov;9(11):1283-1297
pubmed: 34426457
Leuk Res. 1984;8(4):521-34
pubmed: 6590930
Cancer Immunol Immunother. 2017 Aug;66(8):1079-1087
pubmed: 28638976
Haematologica. 2001 Dec;86(12):1261-9
pubmed: 11726317
J Biol Chem. 2014 May 30;289(22):15588-601
pubmed: 24753259
Cytotherapy. 2007;9(2):194-204
pubmed: 17453971
Biomark Res. 2014 Feb 10;2(1):4
pubmed: 24513123
Semin Immunol. 1995 Feb;7(1):13-20
pubmed: 7612890
Cancer Discov. 2017 Feb;7(2):156-164
pubmed: 27986708
Front Immunol. 2018 Feb 15;9:227
pubmed: 29497419
N Engl J Med. 2019 Apr 25;380(17):1628-1637
pubmed: 31018069
Blood Adv. 2018 Apr 24;2(8):848-858
pubmed: 29661755
J Biol Chem. 1999 Apr 23;274(17):11505-12
pubmed: 10206955
Sci Rep. 2016 Oct 11;6:35085
pubmed: 27725776
Drug Discov Today. 2015 Jul;20(7):838-47
pubmed: 25728220
Immunity. 2014 Mar 20;40(3):389-99
pubmed: 24631154
Mol Cancer Ther. 2020 Nov;19(11):2330-2339
pubmed: 32879051
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35288466
Sci Rep. 2021 Oct 27;11(1):21230
pubmed: 34707185
Cell Mol Immunol. 2020 Mar;17(3):272-282
pubmed: 31700117
Blood. 2011 Apr 28;117(17):4542-51
pubmed: 21300981
Clin Cancer Res. 2019 Feb 15;25(4):1358-1368
pubmed: 29959143
J Clin Med. 2019 Aug 20;8(8):
pubmed: 31434267
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
Int Immunol. 2004 Aug;16(8):1055-68
pubmed: 15226269
Cancer Res. 2004 Nov 15;64(22):8443-50
pubmed: 15548716
Mol Cancer Ther. 2020 Sep;19(9):1875-1888
pubmed: 32518207
Curr Oncol Rep. 2020 Jan 29;22(2):11
pubmed: 31997022
Nat Immunol. 2015 Mar;16(3):267-75
pubmed: 25599562
Blood Cells Mol Dis. 2015 Dec;55(4):336-46
pubmed: 26460257
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
J Clin Oncol. 2005 Jun 20;23(18):4110-6
pubmed: 15961759
Cell. 2009 Jul 23;138(2):271-85
pubmed: 19632178
Blood. 2016 Jun 9;127(23):2879-89
pubmed: 27013443
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
J Exp Med. 1997 May 19;185(10):1743-51
pubmed: 9151699
Nat Rev Immunol. 2007 Apr;7(4):255-66
pubmed: 17380156
Front Immunol. 2021 Sep 14;12:717998
pubmed: 34594332
Cancer Immunol Immunother. 2022 Feb;71(2):473-489
pubmed: 34247273
Immunity. 1995 Nov;3(5):635-46
pubmed: 7584153
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Minerva Med. 2020 Oct;111(5):395-410
pubmed: 32955828
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
J Cell Physiol. 2020 Jun;235(6):4989-4998
pubmed: 31709540